 |
|
Knowledge of genetics improves uncertain medication
February 19, 2009Roughly 100,000 Swedes are under treatment with the blood-thinning drug Waran. Patients evince varying sensitivity to Waran, which makes the initiation of treatment a risky balancing act between hemorrhaging and clotting. Now researchers at Uppsala University have developed a model for calculating the appropriate dose before treatment starts. The study appears in the scientific publication New England Journal of Medicine.
Some 20 research teams in four regions of the world have joined together to study whether it is possible to determine the proper dosage of Waran before starting treatment. Data from 5,700 subjects undergoing treatment with Waran were collected from the four parts of the globe. Niclas Eriksson, a statistician at UCR - Uppsala Clinical Research Center - has developed a model for calculating the right dosage of Waran for individuals of European, African, and Asian origin.
"The findings show that with the aid of two genes, VKORC1 and CYP2C9, it is possible to predict what dosage patients will land at," says Niclas Eriksson.
"Almost half of patients have mutations that entail that they need a slightly lower dose than normal, and a small percentage need a much lower dose," says Mia Wadelius, a physician and researcher in clinical pharmacology, Uppsala University Hospital, who was in charge of collecting the data in Sweden.
The next step will be to test this method on patients in health care. This spring an American clinical test will get underway to study whether custom-tailored treatment increases the certainty in treating patients with Waran. Similar clinical testing will start this autumn in seven countries in Europe. A total of 3,000 patients who are starting treatment with blood-thinning medicines will be recruited. The Swedish part of the study will be directed by Mia Wadelius, and the Waran clinics in Uppsala and Skåne will be participating. Patients will start either with a custom-tailored dosage or with the normal dosage and then be compared.
"Even patients receiving a tailored dose need regular tests of the blood's ability to coagulate, since diet and other medicines play a role, but it is our hope that the treatment will be both safer and more secure with tailored dosage," says Mia Wadelius.
Uppsala University
"Almost half of patients have mutations that entail that they need a slightly lower dose than normal, and a small percentage need a much lower dose," says Mia Wadelius, a physician and researcher in clinical pharmacology, Uppsala University Hospital, who was in charge of collecting the data in Sweden.
The next step will be to test this method on patients in health care. This spring an American clinical test will get underway to study whether custom-tailored treatment increases the certainty in treating patients with Waran. Similar clinical testing will start this autumn in seven countries in Europe. A total of 3,000 patients who are starting treatment with blood-thinning medicines will be recruited. The Swedish part of the study will be directed by Mia Wadelius, and the Waran clinics in Uppsala and Skåne will be participating. Patients will start either with a custom-tailored dosage or with the normal dosage and then be compared.
"Even patients receiving a tailored dose need regular tests of the blood's ability to coagulate, since diet and other medicines play a role, but it is our hope that the treatment will be both safer and more secure with tailored dosage," says Mia Wadelius.
Uppsala University
Blood-thinning Current Events and Blood-thinning News RSSMayo Clinic study shows people with heart devices can 'digest' advanced diagnostic technology safely
A new Mayo Clinic study suggests that video capsule endoscopy (CE), a procedure that uses wireless technology in diagnosing intestinal disease, is safe for patients with heart devices.
Clots traveling from lower veins may not be the cause of pulmonary embolism in trauma patients
A report from a team of Massachusetts General Hospital (MGH) physicians calls into question the longstanding belief that pulmonary embolism (PE) - the life-threatening blockage of a major blood vessel in the lungs - is caused in trauma patients by a blood clot traveling from vessels deep within the legs or lower torso.
Designing drugs and their antidotes together improves patient care
Imagine a surgical patient on a blood-thinning drug who starts bleeding more than expected, and an antidote that works immediately - because the blood thinner and antidote were designed to work together.
Study details safe, effective, minimally invasive mitral valve repair
Surgical treatment for mitral valve disease includes either repairing the patient's diseased valve or replacing it with a metal, mechanical valve or an animal tissue valve.
NHLBI stops study of pulmonary hypertension treatment in sickle cell patients
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped a clinical trial testing a drug treatment for pulmonary hypertension in adults with sickle cell disease nearly one year early due to safety concerns.
Right warfarin dose determined by 3 genes
Researchers at Uppsala University, together with colleagues at the Karolinska Institute and the Sanger Institute, have now found all the genes the determine the dosage of the blood-thinning drug warfarin. The findings are published in the scientific journal PLoS Genetics.
Genetic information personalizes warfarin prescribing
Warfarin, one of the world's most widely used drugs, is also one of the trickiest to prescribe. Half of those who take it are at risk of serious problems when given the standard starting dose.
Research highlights new approaches to prevent blood clots
Blood clotting, or coagulation, is an important process that prevents excessive bleeding when a blood vessel is injured.
Simple new method detects contaminants in life-saving drug
The blood-thinning drug heparin is highly effective when used to prevent and treat blood clots in veins, arteries and lungs, but earlier this year its reputation as a lifesaver was sullied when contaminated heparin products caused serious allergic reactions that led to a large number of deaths.
New method identifies rat poison in humans
Researchers at the Norwegian Institute of Public Health (NIPH) have developed a method to identify bromadiolone poisoning in humans. Bromadiolone is a rat poison that can be purchased freely in shops. A number of cases have been reported internationally where people have been poisoned, with a mortality rate of 20 percent.
More Blood-thinning Current Events and Blood-thinning News Articles
 |
Olympian Labs Nattokinase, 100mg by Olympian Labs Nattokinase is a serine protease type enzyme derived from fermented soybeans. Research has shown nattokinase to support healthy coagulation of blood and enhance fibrinolytic (breaking up of clots) activity. Fibrin is a protein that, when activated, forms fibrinogen which is responsible for blood clotting. OL uses only the highly bioavailable, proprietary extract of natto. |
 |
OMEGA 3, 6, 9 ESSENTIAL OILS (100 SOFT GELS) by EMPIRE VITAMINS INC Omega-Plex is cold pressed and solvent-free with Vitamin E added to prevent oxidation. The fish oil in Omega-Plex is obtained from cold water fish. |
 |
Omega 3-6-9 - 100 - Softgel by Now Foods While small percentages of essential fatty acids can be obtained from food, the majority of the population tends to consume far more of the saturated bad fats than essential good fats (Omega-3 and -6). NOW Omega 3-6-9 is an ideally balanced, full-spectrum source of these three good fats. By utilizing high potency Omega-3 from flaxseed and canola, Omega-6 from primrose and black currant and Omega-9 (or Oleic acid, a non-essential fatty acid) from Canola and Flax, our formula helps correct this common imbalance, while minimizing any chance of reoccurring reverse imbalances.* |
 |
Ginkgo Biloba (60 mg--90 capsules) by Great American Health Products Ginko biloba supports memory function, promotes mental sharpness and encourages concentration by helping maintain healthy circulation to the brain. Doctors A-Z® features the powerful GINKGOSELECTTM Ginkgo biloba extract. SUPPLEMENT FACTS: Serving size = 1 capsule. Amount Per Serving: GinkgoSelect® Ginkgo biloba leaf extract (standardized to 24% flavone glycosides, 6% terpene lactones) = 60 mg. Other Ingredients: Trace of microcrystalline cellulose (plant fiber) and gelatin. SUGGESTED USE: As a dietary supplement, take one capsule with water during the morning and evening meals. WARNING: Consult your healthcare provider before use if you are taking a blood-thinning medication. |
 |
Theta Minerals Copper - (16 oz.) by The Wolfe Clinic Copper is most concentrated in the liver, heart, kidneys, brain, bones, and muscles and is essential in the blood. Trace amounts are present in all body tissues. Copper increases iron assimilation, iron and copper work together in the formation of hemoglobin and red blood cells. Anemia can be a copper deficiency symptom. Various enzyme reactions require copper. Copper influences protein metabolism and general healing, improves vitamin C oxidation and is integral in the formation of RNA. Low or high copper levels can be found in those with mental and emotional problems. Copper helps rid the body of parasites, and is beneficial for graying and thinning hair. Copper excess is not common because only a small percentage is assimilated, but toxicity problems can present serious disease states. |
 |
HAIR ENHANCING SHAMPOO WITH DHT BLOCKER SYSTEM by REGENCY COSMETICS Shampoo with DHT blocker system that counteracts and blocks the buildup of DHT. Penetrates the hair shaft and follicles,eliminates layers of DHT buildup,flushes follicles clean to allow normal follicle function . |
| © 2009 BrightSurf.com |